IN2014CN04765A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN04765A IN2014CN04765A IN4765CHN2014A IN2014CN04765A IN 2014CN04765 A IN2014CN04765 A IN 2014CN04765A IN 4765CHN2014 A IN4765CHN2014 A IN 4765CHN2014A IN 2014CN04765 A IN2014CN04765 A IN 2014CN04765A
- Authority
- IN
- India
- Prior art keywords
- methods
- invention concerns
- agents compositions
- concerns anti
- inflammatory agents
- Prior art date
Links
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161577361P | 2011-12-19 | 2011-12-19 | |
| PCT/US2012/068718 WO2013095966A1 (en) | 2011-12-19 | 2012-12-10 | Non-sialylated anti-inflammatory polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN04765A true IN2014CN04765A (enExample) | 2015-09-18 |
Family
ID=48669359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN4765CHN2014 IN2014CN04765A (enExample) | 2011-12-19 | 2012-12-10 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US9587025B2 (enExample) |
| EP (2) | EP2793943B1 (enExample) |
| JP (6) | JP6322872B2 (enExample) |
| CN (2) | CN104010659A (enExample) |
| AU (1) | AU2012355710B2 (enExample) |
| CA (1) | CA2859022A1 (enExample) |
| EA (2) | EA201892339A3 (enExample) |
| ES (1) | ES2692539T3 (enExample) |
| IL (2) | IL233082B (enExample) |
| IN (1) | IN2014CN04765A (enExample) |
| MX (1) | MX357923B (enExample) |
| PT (1) | PT2793943T (enExample) |
| SG (3) | SG10201805962PA (enExample) |
| WO (1) | WO2013095966A1 (enExample) |
| ZA (1) | ZA201405185B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| EA201892339A3 (ru) | 2011-12-19 | 2019-06-28 | Дзе Рокфеллер Юниверсити | Несиалированный выделенный полипептид, способ получения указанного полипептида и фармацевтическая композиция для лечения воспалительного заболевания |
| US12384848B2 (en) | 2011-12-19 | 2025-08-12 | The Rockefeller University | Anti-inflammatory polypeptides |
| WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
| WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
| US9505833B2 (en) | 2012-04-20 | 2016-11-29 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
| US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| WO2015054039A1 (en) * | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Fc CONTAINING POLYPEPTIDES HAVING INCREASED BINDING TO FcGammaRIIB |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| EP3725808B1 (en) | 2014-11-21 | 2024-07-17 | Bristol-Myers Squibb Company | Antibodies against cd73 and uses thereof |
| ES2826566T3 (es) | 2014-11-21 | 2021-05-18 | Bristol Myers Squibb Co | Anticuerpos que comprenden regiones constantes pesadas modificadas |
| KR102644115B1 (ko) | 2014-12-23 | 2024-03-05 | 브리스톨-마이어스 스큅 컴퍼니 | Tigit에 대한 항체 |
| JP2018508522A (ja) * | 2015-03-04 | 2018-03-29 | ザ ロックフェラー ユニバーシティー | 抗炎症性ポリペプチド |
| US10300127B2 (en) * | 2015-03-20 | 2019-05-28 | The Rockefeller University | Immune complex |
| WO2016196228A1 (en) | 2015-05-29 | 2016-12-08 | Bristol-Myers Squibb Company | Antibodies against ox40 and uses thereof |
| WO2017004016A1 (en) | 2015-06-29 | 2017-01-05 | The Rockefeller University | Antibodies to cd40 with enhanced agonist activity |
| FR3038517B1 (fr) * | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| IL307425B2 (en) | 2016-03-04 | 2025-07-01 | Univ Rockefeller | CD40 antibodies with enhanced agonist activity |
| SG11201806861SA (en) | 2016-03-04 | 2018-09-27 | Bristol Myers Squibb Co | Combination therapy with anti-cd73 antibodies |
| WO2018106885A1 (en) | 2016-12-07 | 2018-06-14 | East Carolina University | Compositions and methods for in vitro cultivation and/or expansion of regulatory t cells |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| BR112019024419A2 (pt) | 2017-05-25 | 2020-07-14 | Bristol-Myers Squibb Company | anticorpos compreendendo regiões constantes pesadas modificadas |
| WO2019033087A1 (en) * | 2017-08-11 | 2019-02-14 | Research Development Foundation | MODIFIED FC ANTIBODY VARIANTS FOR ENHANCED SERIAL HALF LIFE |
| AU2018388791B2 (en) | 2017-12-19 | 2025-04-03 | The Rockefeller University | Human IgG Fc domain variants with improved effector function |
| EP3732198A1 (en) | 2017-12-27 | 2020-11-04 | Bristol-Myers Squibb Company | Anti-cd40 antibodies and uses thereof |
| EP3873532A1 (en) | 2018-10-31 | 2021-09-08 | Novartis AG | Dc-sign antibody drug conjugates |
| SG11202104969RA (en) | 2018-11-16 | 2021-06-29 | Bristol Myers Squibb Co | Anti-nkg2a antibodies and uses thereof |
| EP3887397A1 (en) | 2018-11-28 | 2021-10-06 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| WO2021231732A1 (en) | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US20040002587A1 (en) * | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| WO2004031362A2 (en) | 2002-10-03 | 2004-04-15 | Large Scale Biology Corporation | Multimeric protein engineering |
| EP1858925A2 (en) * | 2005-01-12 | 2007-11-28 | Xencor, Inc. | Antibodies and fc fusion proteins with altered immunogenicity |
| RU2007145509A (ru) | 2005-05-09 | 2009-06-20 | Гликарт Биотехнологи Аг (Ch) | Антигенсвязывающие молекулы, имеющие модифицированные fc-участки и измененное связывание с fc-рецепторами |
| SG163548A1 (en) | 2005-06-30 | 2010-08-30 | Centocor Inc | Methods and compositions with enhanced therapeutic activity |
| EP2455100A3 (en) | 2005-11-07 | 2012-11-07 | The Rockefeller University | Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof |
| US8470318B2 (en) | 2005-11-07 | 2013-06-25 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| US20080206246A1 (en) | 2006-04-05 | 2008-08-28 | Ravetch Jeffrey V | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| JP6084761B2 (ja) * | 2006-04-05 | 2017-02-22 | ザ ロックフェラー ユニバーシティー | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
| NZ597651A (en) | 2006-10-26 | 2012-07-27 | Univ Rockefeller | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| CA2673725C (en) * | 2006-12-20 | 2016-01-12 | Mmr Information Systems, Inc. | Antibodies and methods for making and using them |
| BRPI0720861A2 (pt) * | 2006-12-28 | 2014-02-25 | Centocor Ortho Biotech Inc | Métodos e vetores para gerar imunoglobulinas asialiladas |
| WO2008138017A2 (en) | 2007-05-08 | 2008-11-13 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for modifying t cell immune responses and inflammation |
| CN103626875B (zh) * | 2007-05-30 | 2016-01-13 | 浦项工科大学校产学协力团 | 免疫球蛋白融合蛋白 |
| CN102037004A (zh) * | 2008-01-08 | 2011-04-27 | 生物种属学股份公司 | 使用寡糖基转移酶的多肽的糖缀合 |
| WO2009132130A2 (en) | 2008-04-22 | 2009-10-29 | The Rockefeller University | Methods of identifying anti-inflammatory compounds |
| KR101965585B1 (ko) * | 2009-10-29 | 2019-04-04 | 얀센 바이오테크 인코포레이티드 | 항체 글리코실화 변이체 |
| KR101960109B1 (ko) * | 2010-11-30 | 2019-03-20 | 추가이 세이야쿠 가부시키가이샤 | 세포상해 유도 치료제 |
| EP2656073A4 (en) * | 2010-12-20 | 2014-12-17 | Univ Rockefeller | Modulating agonistic tnfr antibodies |
| WO2012139069A2 (en) * | 2011-04-07 | 2012-10-11 | Neotope Biosciences Limited | Compositions and methods for treating diseases of protein aggregation involving ic3b deposition |
| US20130273089A1 (en) * | 2011-11-03 | 2013-10-17 | Tolera Therapeutics, Inc. | Antibody and methods for selective inhibition of t-cell responses |
| EA201892339A3 (ru) * | 2011-12-19 | 2019-06-28 | Дзе Рокфеллер Юниверсити | Несиалированный выделенный полипептид, способ получения указанного полипептида и фармацевтическая композиция для лечения воспалительного заболевания |
-
2012
- 2012-12-10 EA EA201892339A patent/EA201892339A3/ru unknown
- 2012-12-10 CA CA2859022A patent/CA2859022A1/en active Pending
- 2012-12-10 SG SG10201805962PA patent/SG10201805962PA/en unknown
- 2012-12-10 CN CN201280062837.8A patent/CN104010659A/zh active Pending
- 2012-12-10 MX MX2014007292A patent/MX357923B/es active IP Right Grant
- 2012-12-10 IN IN4765CHN2014 patent/IN2014CN04765A/en unknown
- 2012-12-10 EA EA201491215A patent/EA031715B1/ru unknown
- 2012-12-10 SG SG10202001596VA patent/SG10202001596VA/en unknown
- 2012-12-10 WO PCT/US2012/068718 patent/WO2013095966A1/en not_active Ceased
- 2012-12-10 PT PT12860516T patent/PT2793943T/pt unknown
- 2012-12-10 AU AU2012355710A patent/AU2012355710B2/en active Active
- 2012-12-10 JP JP2014549097A patent/JP6322872B2/ja active Active
- 2012-12-10 CN CN202311583469.8A patent/CN117964709A/zh active Pending
- 2012-12-10 SG SG11201403311SA patent/SG11201403311SA/en unknown
- 2012-12-10 EP EP12860516.9A patent/EP2793943B1/en active Active
- 2012-12-10 ES ES12860516.9T patent/ES2692539T3/es active Active
- 2012-12-10 EP EP18196115.2A patent/EP3485909A1/en active Pending
- 2012-12-10 US US14/368,701 patent/US9587025B2/en active Active
-
2014
- 2014-06-12 IL IL233082A patent/IL233082B/en active IP Right Grant
- 2014-07-15 ZA ZA2014/05185A patent/ZA201405185B/en unknown
-
2015
- 2015-03-04 US US14/638,905 patent/US9845358B2/en active Active
-
2017
- 2017-12-18 US US15/845,487 patent/US10894832B2/en active Active
- 2017-12-27 JP JP2017251227A patent/JP2018093874A/ja active Pending
-
2019
- 2019-08-19 IL IL268787A patent/IL268787B/en unknown
- 2019-11-22 JP JP2019211501A patent/JP7044267B2/ja active Active
-
2020
- 2020-11-20 US US16/953,639 patent/US11608379B2/en active Active
- 2020-11-25 US US17/104,125 patent/US11613579B2/en active Active
-
2021
- 2021-01-07 JP JP2021001368A patent/JP2021063117A/ja active Pending
-
2022
- 2022-03-04 JP JP2022033240A patent/JP2022091768A/ja active Pending
-
2024
- 2024-06-26 JP JP2024102976A patent/JP2024125369A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN04765A (enExample) | ||
| MX365614B (es) | Composiciones utiles para tratar trastornos relacionados con kit. | |
| GB2494845B (en) | Compositions and methods for treating automotive surfaces | |
| PH12015500525A1 (en) | Formulations of enzalutamide | |
| PH12014500995A1 (en) | Pak inhibitors for the treatment of cell proliferative disorders | |
| MX2014010481A (es) | Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica. | |
| IN2015DN00127A (enExample) | ||
| PH12013502623A1 (en) | Metalloenzyme inhibitor compounds | |
| PH12013502622A1 (en) | Metalloenzyme inhibitor compounds | |
| IL229276B (en) | Methods of treating or preventing cholesterol related disorders | |
| PH12013502624A1 (en) | Metalloenzyme inhibitor compounds | |
| WO2012149472A9 (en) | Methods, compositions, and kits for treating and preventing neurological conditions | |
| IL232710A0 (en) | l-serine preparations, methods and uses for the treatment of neurodegenerative diseases and disorders | |
| EP3126004A4 (en) | Methods and compositions for treating inflammatory disorders | |
| PL2906594T3 (pl) | Sposoby i kompozycje do leczenia stwardnienia rozsianego oraz odnośnych zaburzeń | |
| IL231158A0 (en) | Preparations and methods for the treatment of neurodegenerative diseases | |
| WO2013023151A3 (en) | Compositions and methods for treating celiac sprue disease | |
| IL231157A0 (en) | Preparations and methods for the treatment of neurodegenerative diseases | |
| WO2013023059A3 (en) | Methods and compositions for the treatment of autoimmune and inflammatory diseases | |
| WO2011112588A9 (en) | Compositions and methods for treating inflammatory disorders | |
| IN2015DN01524A (enExample) | ||
| MX2014000878A (es) | Composiciones y metodos para reducir la incidencia de transtornos digestivos equinos. | |
| WO2012145209A3 (en) | Anti-inflammatory agents | |
| IN2014DN00254A (enExample) | ||
| AP2013007056A0 (en) | Methods and compositions for treating kidney disorders |